Farxiga reduces risk of kidney failure

Sunday 30 August 2020

United Kingdom

A Phase 3 trial of Farxiga (dapagliflozin) has shown a reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease, according to the developer AstraZeneca Plc.  The trial results were presented on 30 August at a virtual meeting of the European Society of Cardiology. Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor which has been approved to treat Type 2 diabetes and heart failure.